R. Kate Kelley, MD

Gastrointestinal oncologist

Dr. R. Kate Kelley is a gastrointestinal oncologist who treats liver cancers such as hepatocellular carcinoma; bile duct cancers such as cholangiocarcinoma; gastric cancer; esophageal cancer; anal, colon and rectal cancer; pancreatic cancer; and gastrointestinal stromal tumors. In her research, her interests include developing clinical trials to identify new treatments for gastrointestinal malignancies, particularly hepatocellular carcinoma and bile duct cancers.

Kelley graduated from UCLA School of Medicine and completed a residency at UCLA, where she was chief resident in Internal medicine. She also completed a fellowship in hematology and oncology at UCSF. She received the American Society of Clinical Oncology (ASCO) Young Investigator Award in 2010 and the Gastrointestinal Cancers Symposium ASCO Foundation Merit Award in 2009. Kelley is co-author of a chapter on alimentary cancers in the textbook Current Medical Diagnosis and Treatment.

Clinics

Gastrointestinal Medical Oncology Clinic
1825 Fourth St., Fourth Floor
San Francisco, CA 94158
Phone: (415) 353-9888
Fax: (415) 353-9931

Hours: Monday to Friday
8 a.m. – 5 p.m.

Pancreas Center
1825 Fourth St., Fourth Floor
San Francisco, CA 94158
Patient Information and Appointments: (415) 353-9888
Administrative Inquiries: (415) 476-3270
Fax: (415) 353-9931

Hours: Monday to Friday
8 a.m. — 5 p.m.

Conditions & Treatments

Board Certification

Hematology, American Board of Internal Medicine
Medical Oncology, American Board of Internal Medicine

Academic Title

Associate Professor

More about R. Kate Kelley

Additional Languages

Spanish

Education

UCLA School of Medicine 2002

Residencies

UCLA Medical Center, Internal Medicine 2005

Fellowships

UCSF Medical Center, Hematology - Oncology 2009

Selected Research and Publications

  1. Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, Blanc JF, Bolondi L, Kl├╝mpen HJ, Chan SL, Zagonel V, Pressiani T, Ryu MH, Venook AP, Hessel C, Borgman-Hagey AE, Schwab G, Kelley RK. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018 Jul 05; 379(1):54-63.
  2. Lim HC, Montesion M, Botton T, Collisson EA, Umetsu SE, Behr SC, Gordan JD, Stephens PJ, Kelley RK. Hybrid Capture-Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in BRCA1-Mutant Cholangiocarcinoma Harboring a Novel YWHAZ-BRAF Fusion. Oncologist. 2018 Apr 05.
  3. Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, El-Khoueiry A, Kelley RK, Borbath I, Choo SP, Oh DY, Philip PA, Chen LT, Reungwetwattana T, Van Cutsem E, Yeh KH, Ciombor K, Finn RS, Patel A, Sen S, Porter D, Isaacs R, Zhu AX, Abou-Alfa GK, Bekaii-Saab T. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. J Clin Oncol. 2018 Jan 20; 36(3):276-282.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.